Belgian-based UCB is the ninth drug company to impose limits on 340B pricing involving contract pharmacies.

UCB Becomes Ninth Drug Manufacturer to Announce 340B Contract Pharmacy Limits

In Pharma IndustryNovember 23, 2021611 Views

Belgian-based pharmaceutical manufacturer UCB this morning became the ninth drug company to impose limits on 340B pricing involving contract pharmacies.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga

Exact matches only

Search in title

Search in content

Search in excerpt

Hidden